Lv11
90 积分 2023-10-27 加入
A Mechanistic Physiologically‐Based Pharmacokinetic Platform Model to Guide Adult and Pediatric Intravenous and Subcutaneous Dosing for Bispecific T Cell Engagers
4小时前
待确认
Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy
7天前
已完结
Bispecific and multispecific antibodies in oncology: opportunities and challenges
18天前
已完结
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer
19天前
已完结
Small cell lung cancer
19天前
已完结
Nanobody-enhanced T cell cancer immunotherapy: Advancing precision medicine
25天前
已完结
Breast cancer
26天前
已完结
Advances in the treatment of systemic lupus erythematosus
27天前
已完结
Clinical Pharmacology Characterization of Bispecific T‐Cell Engagers: A Summary Based on FDA Approvals
28天前
已完结
Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study
1个月前
已完结
皖公网安备34019202002308
